Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could fat extract be the key to faster wound healing?

NCT ID NCT07372404

Symptom relief Sponsor: Linio Biotech Oy Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a cream made from human fat can help skin graft donor sites heal faster and form better scars. Thirty adults getting skin grafts will have two donor sites: one treated with the fat extract and the other with standard care. Researchers will compare healing time, scar quality, and any side effects over 60 days.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
allogeneic human fat-derived extract (topical)
What this could lead to
If it works, this could lead to a simple, safe way to help skin graft donor sites heal faster and with better scars.
What could go wrong
This is a small early-stage trial with only 30 people, so results may not apply to everyone. The extract might not improve healing or could cause irritation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2023

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Wound of at least 10 cm3 with an indication of skin graft surgery (two skin grafts harvested and used) * Adult (age 18 years or more) * Able and willing to give informed consent * Reasonably accessible to the study clinic and compliant to wound treatment Exclusion Criteria: * Known allergy to any of the preparation used in the study (Tience) * Systemic cancer (does not include carcinoma in situ of the cervix or local skin cancers such as basiloma) * Pregnancy or nursing * Those who withhold consent * Active infection on the receptor site, donor site or sepsis * Any other serious disease likely to compromise the outcome of the trial, such as critical renal disease (creatinine greater than 300 mmol/l) * Those living at such a distance from the clinic as would make frequent assessment visits inappropriately expensive and/or impractical. * Those with conditions, which tend to limit a patient´s ability or willingness to restrict activities or comply with the instructions during the treatment and follow-up period.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Wound healing are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Wound healing

Contacts and locations

Locations

  • Hospital Nova

    Jyväskylä, Finland, 40620, Finland

More trials for these conditions

Other studies related to the condition(s) this trial covers.